The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
Vyjuvek Gel, 1st Topical Gene Therapy, Poised for Approval in Japan
A Japanese health ministry panel on July 7 endorsed the approval of Vyjuvek Gel (beremagene geperpavec), a topical gene therapy developed by US upstart Krystal Biotech, for the treatment of dystrophic epidermolysis bullosa (DEB), a rare genetic skin disorder. If…
To read the full story
Related Article
- Krystal Launches Japan’s First DEB Therapy Vyjuvek Gel
October 22, 2025
- Listing OK’ed for Krystal’s Vyjuvek Gel, Japan’s First Topical Gene Therapy
October 16, 2025
- Japan to Apply Drug Pricing Rules for Krystal Gene Therapy: Chuikyo
August 28, 2025
- Krystal Biotech Snags Japan Nod for Vyjuvek as 1st Topical Gene Therapy
July 29, 2025
REGULATORY
- LDP League Formally Urges Male HPV Shots Under NIP from FY2026
December 17, 2025
- MHLW Drafts Guideline Update, Urges Makers to Factor Distribution Costs into WPPs
December 16, 2025
- MHLW to Add Company-Driven Route to “Specific-Use Drug” Designations
December 16, 2025
- MHLW Council Determines 3 “Drug Loss” Products as High-Need, to Seek Development
December 16, 2025
- LDP Biosimilar Group Submits Request to Finance Minister, Seeks Continued Support
December 16, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…